通讯作者: 曲颜丽, qumedical@163.com

DOI：10.12201/bmr.202409.00052

Efficacy and safety of preoperative chemotherapy in real world patients with locally advanced gastric/gastroesophageal junction adenocarcinoma

• 摘要：目的:回顾性分析真实世界中局部晚期胃/胃食管结合部腺癌患者两药或三药术前化疗的疗效及安全性。方法:回顾性收集新疆医科大学附属肿瘤医院2016年1月至2021年12月之间收治的cT3-4N+M0胃/胃食管结合部腺癌并接受新辅助化疗后手术的患者,根据纳入排除标准,共收集112例,其中两药组36例,三药组76例。所有患者均行术前化疗及术后辅助治疗。结果:两药/三药方案对患者的OS、DFS、R0切除率、肿瘤降级无显著差异(P>0.05)；患者年龄、手术方法、肿瘤的降级、术后病理分期、病理分化类型是影响患者OS与DFS独立危险因素(P<0.05)。结论:两药或三药术前化疗方案对患者的预后、肿瘤的降期、R0/R1切除并无显著影响,但是患者年龄、术后病理分期、肿瘤的降级、病理分化类型对患者的预后有一定影响。

  关键词： 局部晚期胃癌; 术前化疗 肿瘤降级; ; ; 

   

  Abstract: Objective: To retrospectively analyze the efficacy and safety of preoperative chemotherapy of two or three drugs in patients with locally advanced gastric/gastroesophageal adenocarcinoma in the real world. Methods: Retrospective collection of cT3-4N+M0 gastric/gastroesophageal adenocarcinoma admitted to the Affiliated Cancer Hospital of Xinjiang Medical University between January 2016 and December 2021 and underwent surgery after neoadjuvant chemotherapy. According to the exclusion criteria, a total of 112 cases were collected, including 36 cases in the two drug group, 76 cases in the three-drug group. All patients underwent preoperative chemotherapy and postoperative adjuvant treatment. Results: There is no significant difference between the two-drug/three-drug regimen for the patients OS, DFS, R0 rate, tumor downgrade(P>0.05); the patients age, surgical method, tumor downgrade, postoperative pathological staging, and pathological differentiation type are the independent risk factors affecting the patients OS and DFS (P<0.05). Conclusion: The preoperative chemotherapy regimen of two or three drugs has no significant impact on the prognosis of the patient, the decline of the tumor, and the resection of R0/R1, but the patients age, postoperative pathological staging, the downgrade of the tumor, and the pathological differentiation type have a certain impact on the prognosis of the patient.

  Key words: Locally; advanced gastric; cancer? Preoperative; chemotherapy? Tumor; downgrade

  提交时间：2024-09-23

  版权声明：作者本人独立拥有该论文的版权，预印本系统仅拥有论文的永久保存权利。任何人未经允许不得重复使用。
• html

• 图表

• 郝雅琴, 胡云峰, 郝静, 赵鑫. 环状RNA与自噬在胃癌中作用的研究进展. 2023. doi: 10.12201/bmr.202304.00001

  龚悦, 吴欢, 骆玉霜. 循环肿瘤细胞HER-2表达在胃腺癌靶向治疗中的应用. 2024. doi: 10.12201/bmr.202408.00001

  王耀强, 汪浩浩, 罗长江. HMGB1在胃癌进展和治疗中的作用. 2024. doi: 10.12201/bmr.202412.00009

  杨雷, 周梦倩, 汤铜. 术前淋巴结超声特征对甲状腺癌颈侧区淋巴结转移风险的预测. 2024. doi: 10.12201/bmr.202410.00035

  田梦娇, 张爱琴. 卵巢癌术后分型辨治经验. 2024. doi: 10.12201/bmr.202411.00016

  岳晓雪, 赵群. 年轻化疗耐药绒癌病例1例及文献复习. 2024. doi: 10.12201/bmr.202411.00007

  秦金华, 刘超毅, 洪源, 曾嘉慧. AIGC全病程消息推送平台在肿瘤手术室的应用. 2024. doi: 10.12201/bmr.202412.00036

  刘亚茹, 石浩, 孙冠群, 董静静, 叶寒锋, 郑乐一, 苏丹. 肿瘤患者免疫治疗后智能远程管理系统设计研究. 2022. doi: 10.12201/bmr.202206.00007

  刘永淳, 罗良涛, 高忠英. 高忠英教授从“胃痈”理论治疗慢性萎缩性胃炎的经验. 2024. doi: 10.12201/bmr.202410.00062

  李森强, 冯琦, 宋才渊, 李伦辛. 张氏清热消瘀汤联合VSD治疗胫腓骨开放性骨折创面感染疗效及安全性. 2024. doi: 10.12201/bmr.202410.00023

• 序号	提交日期	编号	操作
  1	2024-07-01	bmr.202409.00052V1	下载

• 公开评论  匿名评论  仅发给作者 提交评论